COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes

PHASE2TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 29, 2022

Primary Completion Date

August 31, 2024

Study Completion Date

November 30, 2024

Conditions
Covid19SARS-CoV Infection
Interventions
DRUG

Fisetin

\~20 mg/kg/day oral, NG or D tube course for 2 consecutive days twice (Days 0 \& 1 and Days 8 \& 9)

DRUG

Placebo

Placebo looks exactly like the treatment drug, but it contains no active ingredient

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Mayo Clinic

OTHER

NCT04537299 - COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes | Biotech Hunter | Biotech Hunter